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Abstract
Objective
To evaluate the extent to which the inter-institutional, inter-disciplinary mobilisation of data and
skills in the Farr Institute contributed to establishing the emerging field of data science for health in
the UK.
Design and Outcome measures
We evaluated evidence of six domains characterising a new field of science:
• defining central scientific challenges,
• demonstrating how the central challenges might be solved,
• creating novel interactions among groups of scientists,
• training new types of experts,
• re-organising universities,
• demonstrating impacts in society.
We carried out citation, network and time trend analyses of publications, and a narrative review
of infrastructure, methods and tools.
Setting
Four UK centres in London, North England, Scotland and Wales (23 university partners), 2013-2018.
Results
1. The Farr Institute helped define a central scientific challenge publishing a research corpus,
demonstrating insights from electronic health record (EHR) and administrative data at each stage
of the translational cycle in 593 papers with at least one Farr Institute author affiliation on PubMed.
2. The Farr Institute offered some demonstrations of how these scientific challenges might be
solved: it established the first four ISO27001 certified trusted research environments in the UK, and
approved more than 1000 research users, published on 102 unique EHR and administrative data
sources, although there was no clear evidence of an increase in novel, sustained record linkages. The
Farr Institute established open platforms for the EHR phenotyping algorithms and validations (>70
diseases, CALIBER). Sample sizes showed some evidence of increase but remained less than 10% of
the UK population in primary care-hospital care linked studies. 3.The Farr Institute created novel
interactions among researchers: the co-author publication network expanded from 944 unique co-
authors (based on 67 publications in the first 30 months) to 3839 unique co-authors (545 papers in
the final 30 months). 4. Training expanded substantially with 3 new masters courses, training >400
people at masters, short-course and leadership level and 48 PhD students. 5. Universities reorganised
with 4/5 Centres established 27 new faculty (tenured) positions, 3 new university institutes. 6.
Emerging evidence of impacts included: > 3200 citations for the 10 most cited papers and Farr
research informed eight practice-changing clinical guidelines and policies relevant to the health of
millions of UK citizens.
Conclusion
The Farr Institute played a major role in establishing and growing the field of data science for health
in the UK, with some initial evidence of benefits for health and healthcare. The Farr Institute has
now expanded into Health Data Research (HDR) UK but key challenges remain including, how to
network such activities internationally.
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What is already known
• National research initiatives in data science for health are
underway in several countries seeking to harness insights
from electronic health record (EHR) and administrative
data at regional and national scale for patient and public
benefit.
• One approach to grow this emerging field, adopted by
the UK, was to establish a dedicated national research
institute, the Farr Institute.
• We do not know how effective such initiatives are. Multi-
centre, inter-disciplinary research initiatives are com-
mon, but there is a lack of research evaluating such
initiatives particularly national research institutes.
• The Farr Institute ran from 2013 until 2018 when its
larger-scale successor, Health Data Research (HDR) UK,
was established.
What this study adds
• We provide a framework of six domains relevant for
evaluating new inter-institutional, inter-disciplinary ini-
tiatives seeking to establish and grow an emerging field
of science: defining central scientific challenges, demon-
strating how the central challenges might be solved,
creating novel interactions among groups of scientists,
training new types of experts, re-organising universities,
demonstrating impacts in society.
• We show that the Farr Institute created new activities
in and across each of the six domains for developing a
distinctive research field.
• The Farr Institute demonstrated the ability of multiple
UK health research funders and multiple universities to
partner in mobilising data, methodology and expertise
across disciplines, organisations and information gover-
nance domains, resulting in a larger scale of research
and improved methodology.
• We have demonstrated globally relevant challenges and
opportunities for developing data science for health
across instutional and disciplinary barriers, consistent
with the need for big investigation not simply big data.
• First, there is a need for a framework by which HDR UK
and other national research initiatives might be more
rigorously evaluated.
Introduction
Rationale for national initiatives in data sci-
ence for health
Countries across the globe are increasing efforts to harness re-
search insights from EHR and administrative data. A common
theme across these initiatives is to access data for research on a
bigger scale (number of subjects included in analyses) and with
greater detail of clinical and related information, in order to
advance a wide range of research: from disease causation and
classification to drug discovery, translational research, clini-
cal trials, evidence-based medicine, clinical practice and public
health. While many fields of science have few relevant national
borders, data science for health has inherent national and re-
gional dimensions: regional clinical knowledge is required to
understand the context and validity of data, and countries
differ in the legal, political, economic and public opinion con-
text shaping the research using such data. Countries differ
in their approach, for example: nationwide administrative and
registry data in Nordic countries [1–4]; province –wide initia-
tives in Canada [5] and Australia [6], networks of hospitals in
the German Medical Informatics Initiative [7] and US PCOR-
net [8]; and genomics/precision medicine initiatives linked to
EHRs such as the US Million Veteran Program [9] and All of
Us [10].
UK establishes national research institute
The UK decided a national research institute was necessary to
develop and deliver data science for health in order to lever-
age the NHS and allied data sources. The UK has a popu-
lation of 65 million, a single payer health system (one NHS),
a unique identifier for its citizens’ health data, long-standing
population-wide EHRs, and 2.2 million citizens in consented
cohorts, many with genomic and other detailed research data
[11], and an ambition to have 5 million NHS patients with
sequenced genomes [12].
The Farr Institute was established in 2013 (supplementary
Box 1) to leverage these assets and build capabilities to do
research that could only, or best, be done at national scale.
The funding for the Farr Institute came from a consortium
of ten government and charitable research funders, awarding
four academic centres (Scotland, Wales, Northern England
and London), involving partnerships across 21 universities in
the four centres (Figure 1). In 2018 the Farr Institute made
way for the expanded successor institute, HDR UK, with new
centres and longer-term core funding (a comparison of the Farr
Institute and HDR UK is shown in Table 1).
Objectives
Empirical evaluations of inter-institutional, inter-disciplinary
research initiatives, or indeed national research institutes, have
seldom been reported [13, 14]. Evaluations may be conflicted
by an interest in persuading funders to continue support. The
Farr Institute does not have such a conflict and thus provides
an opportunity to learn from its five years of experience. The
Farr Institute was a national experiment in how to build the
foundations for a new research field of data science for health
at scale. In the absence of a well-established framework for
evaluating national research institutes, we based our evalua-
tion on the domains of a new field of science, following pre-
vious literature [15] and the initial strategy [16] of a research
institute in a different field of science, but also launching in
2013 (the Francis Crick Institute).
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Figure 1: UK map of four Farr Institute Centres and partners (N=23)
Box: Domains for evaluating new field of science and sources of evidence used
Domain Source of information
Defining central scientific challenges Strategy documents
Themes, scale, sources, linkages, from 100 most significant
publications
Demonstrating how the central challenges might be solved Survey of Farr Centres: infrastructure, new data made acces-
sible, EHR phenotyping
Novel interactions among groups of scientists Co-author publication networks, based on all publications with
Farr affiliation n=3200
Training new types of experts Survey of Farr Centres
Re-organising Universities Survey of Farr Centres
Demonstrating impacts in society Clinical guidelines and policy documents citing Farr Institute
research, changing practice.
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Methods
We evaluated six inter-related domains of a new field of sci-
ence (see Box), and for each domain sought evidence (publicly
accessible and peer reviewed where available) of change during
the five years of the Farr Institute (April 2013-March 2018).
The evaluation was retrospective and was not planned in 2013.
Defining central scientific challenges
In order to evaluate how the Farr Institute defined central sci-
entific challenges we analysed published strategy documents
and annual reports (available on the Farr Institute website) and
invited each Centre to nominate their most scientifically signif-
icant publications (25 per centre, 100 total). We (QL and HH)
extracted information from these 100 full text publications on
attribution to the Farr Institute, different science themes, dis-
ease area, scale, number of data sources, new record linkages,
and evidence of science impact from citation tracking (Google
Scholar, accessed September 2019).
To be eligible, each publication reported the use of one
or more source of EHR or administrative data or methods di-
rectly relevant to data science. Consented studies without use
of such EHR or administrative data were not eligible. We
classified research themes (following strategy documents) as:
citizen driven health, discovery science, quality and outcomes,
trials and public health. We defined attribution to the Farr
Institute as at least one author who: listed Farr Institute as
an author affiliation in PubMed, acknowledged funding for the
Farr Institute, or was in receipt of funding from the Farr Insti-
tute. Data sources were classified as primary care, hospital dis-
charge data (e.g., Hospital Episode Statistics for England, Pa-
tient Episode Database for Wales, Scottish Morbidity Record),
detailed hospital data, disease and procedure registries, mor-
tality, other health, and socio-economic and other non-health
data. We extracted for each publication the number of peo-
ple providing the denominator population (sample size) and
classified the population as healthy (general population sam-
ple) or based on specific disease or procedure. We carried out
a structured survey with each Centre completing information
on how the central challenges might be solved in three areas:
e-infrastructure and platforms for accessing and sharing data,
new data sources made available for researchers, and EHR
phenotyping methods for structured and unstructured data.
For novel interactions among groups of scientists we anal-
ysed peer reviewed publications. In addition to the in-depth
analysis of the self nominated 100 most significant publica-
tions, we also sought to identify all publications with at least
one author listing a Farr affiliation. We searched PubMed
from inception to 18 September 2018, using the strategy ‘Farr
Institute[AD]’. We visualised the change over time in scien-
tist network behaviour in the Farr Institute, with co-author
publications networks based on all publications returned from
PubMed, using Cytoscape cross-institution activity by year of
publication. We analysed co-author publication network and
inter-disciplinarity by the halfway time point, comparing the
first vs the final 30 months of the Farr Institute.
For training new types of experts and Re-organising Uni-
versities, we carried out a structured survey across centres.
For impact in society, we identified clinical guidelines and
policy documents citing Farr Institute publications through an-
nual reports to funders, automated software used by funders
to capture a range of outputs and impacts (Researchfish) and
by contacting investigators.
Results
Defining central scientific challenges
The Farr Institute published a research corpus around a cen-
tral scientific challenge, demonstrating insights from EHRs and
administrative data. Figure 2 (top panel) illustrates the chal-
lenges of the Farr Institute and (middle panel) demonstrates
the corresponding research publication corpus. The propor-
tion (%) of publications at different stages of the translational
cycle was: methods (17%), patient involvement (3%), discov-
ery science (8%), health services research (24%), clinical trials
(5%) and public health (42%). The Farr Institute published
highly-cited papers using EHR at each stage in the transla-
tional cycle (the top 10 are shown in Table 2), with a total of
3200 citations. Four of these highly-cited papers illustrate the
higher resolution of using linked EHR [17–20]. These different
research themes were applied across different clinical areas,
including cardiometabolic, maternity and child health, mental
health, cancer, renal and respiratory.
There was some evidence of a modest increase in the scale
(number of people analysed in the denominator population) of
research over time in these publications (Figure 3), based on
linked primary-secondary care data in adults. But by 2018 this
represented only 6.15% of the UK population [21]. There was
just one paper that used the whole of England’s hospitalisation
data: Freemantle and colleagues [22] analysing weekend mor-
tality effects using 14.8 million admissions, and several using
all England’s deaths data.
Demonstrating how the central challenges
might be solved: access to research-ready
data
In 2013 there were no independently accredited Trusted Re-
search Environments (TRE) for NHS data: by 2018 there were
four (one in each centre) ISO 27001:2013 certified data safe
havens (Table 3a). The TREs provide secure remote access, a
safe environment for the analysis of sensitive patient identifi-
able data, a pre-requisite for receiving unconsented, individual
level health data for research use. We found evidence that Farr
activity enabled other scientific fields: with over 1000 approved
users on these four data safe havens working on over 300 re-
search projects (the majority being external, having no Farr In-
stitute funding). The Farr Institute enabled the research use of
diverse anonymised patient records, linked across primary care
and secondary care, including NHS imaging data, blood labo-
ratory values and reimbursed prescriptions (Table 3b). There
was a cumulative total of 102 unique data sources reported in
these publications (Figure 4a), with 13% from primary care,
17% limited coded hospital data, 8% detailed hospital data,
19% registries of disease and procedures, 26% socio-economic
and environment, 6% death data and 12% other health data.
The setting and names of each unique data source reported in
these publications are shown in Supplementary Table 1. We
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Figure 2: Central scientific challenges of the Farr Institute
found that the median number of record sources per publi-
cation showed no evidence of increasing, and if anything de-
creased over the 5 years (Figure 4b).
Demonstrating how the central challenges
might be solved: phenotyping
In 2013 there were no openly accessible portals for defining
diseases and health-related conditions using EHR data (EHR
‘phenotyping’). The Farr Institute supported several initiatives
in disease phenotyping (Table 3c): these included CALIBER,
an open platform [23] of re-usable EHR phenotypes (code lists
+ logic + validations) for over 70 diseases which have been
re-used in more than 50 publications with more than 80 ongo-
ing projects [24]. In addition, there were several publications
of EHR phenotypes in Wales and Scotland [25] and a clinical
code repository [26].
Methods of surfacing the entire structured and unstruc-
tured data in a hospital have now been demonstrated in three
hospitals with CogStack and SemEHR [27].
Creating Novel interactions among groups of
scientists
Based on author affiliation, the search [Farr Institute[AD]] on
PubMed returned 594 unique publications (from inception to
18 September 2018). Figure 5 shows that there was a large
expansion of co-author publication networks comparing the
first 30 months (67 publications with 944 unique co-authors)
and the final 30 months (545 papers and 3839 unique co-
authors). Supplementary Figure 4 shows that overall across
the 100 publications, 28% included Farr Institute as both au-
thor affiliation and funder acknowledgement, 14% as author
affiliation only, 11% as funder acknowledgement only and 42%
as Farr-funded investigator only, as confirmed by the centres.
There was some evidence that over time both author affili-
ation and funder acknowledgement increased. Based on the
departmental affiliation of co-authors there was some evidence
of greater inter-disciplinarity in the last 30 months of the Farr
Institute compared to the initial 30 months (Supplementary
Figure 5). We identified 17% of publications involving univer-
sities from across two or more Farr Centres.
We explored the number of publications among the top
100 papers with an international (non-UK) author affiliation
and found the total number of publications as follows: 17 pub-
lications non-Nordic Europe, 11 US, 10 Nordic, 8 Canada, 4
Australia and 2 China.
Among the 100 papers identified by the Farr Institute, 87
were found in the Scopus database, which provides structured
institution data used to generate Supplementary Figure 6. The
median (IQR) number of universities per Farr Institute pub-
lication was 3 (IQR: 2-4) in 2013 and 6 (IQR: 4-8) in 2018
(Supplementary Figure 6). In April 2017 the Farr Institute with
the European Federation of Medical Informatics attracted over
850 delegates from around the world to Informatics for Health
[28] – the UK’s largest health and biomedical informatics re-
search gathering to date.
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Figure 3: Sample size as a percentage of total UK population reported in research publications
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Figure 4a: Cumulative total of unique electronic health record data sources reported in Farr Institute publications
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Figure 4b: Number of electronic health record data sources reported in each publication (from Farr top 100)
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Figure 5: Change in co-author publication networks between the first and final 30-month periods (each dot represents a unique
author: lines connect authors publishing together)
a) First 30 months
b) final 30 months
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Training new types of experts
The Farr Institute Centres created eight new training pro-
grammes at masters, short-course and leadership level across
the four Farr Centres (Table 4). In total 2102 people were
trained in informatics and directly relevant courses across the
4 Centres. As well as conventional programmes - there were 48
PhD students directly funded by the Farr Institute – the Farr
Institute also established a competitively awarded Farr Future
Leaders residential programme with two cohorts of 21 mid-
career researchers with facilitation of national research collab-
orations in conjunction with leadership training.
Re-organising Universities
Universities associated with the Farr Institute established new
institutes and structures (cost centres) for health informat-
ics and data science. At UCL (Institute of Health Informat-
ics, 2014), University of Manchester (Division of Informatics,
Imaging and Data Sciences, Health eResearch Centre), Edin-
burgh (Usher Institute of Population Sciences and Informat-
ics), Swansea University (Patient and Population Health Infor-
matics). These universities established 24 Faculty (tenured)
posts as enduring leverage of the Farr award.
Demonstrating impacts in society
Farr Institute research at different stages of the translational
cycle was cited in and informed practice-changing clinical
guidelines and policies Table 5. These examples included re-
search in public health (WHO guideline recommendations on
video observed therapy for TB), clinical risk prediction (Euro-
pean Society of Cardiology), drug regulatory approvals (NICE
potentially affecting the type or duration of drug treatment),
and implementation of genomic medicine. The change in prac-
tice recommendations potentially affects more than a million
UK citizens.
More widely Farr informatics research informed changes
in government strategy from a centralised to a decentralised
approach to integrating place-based health and administrative
data for multiple analytic purposes [29]. This work also gener-
ated a £20m pilot of problem-based data integration, pulling
through data by addressing care pathway blockages and re-
search questions of importance to the local community in re-
gions of 3-5m population [30]. This became the blueprint for
England’s Local Health and Care Record Exemplars [31].
Discussion
Clinicians, patients and policy makers have growing expecta-
tions of the use of data to provide research insights with the
potential to improve health and care outcomes [32]. New sci-
entific fields tend to have high-priority defining characteristics;
we provide evidence in six recognized domains suggesting the
Farr Institute played a major role in establishing and growing
the field of data science for health in the UK. The experience
of the Farr Institute has informed the design of Health Data
Research UK (HDR UK), and this evaluation is relevant to
the inter-institution, inter-disciplinary challenges of scaling up
health science around big data in many parts of the world.
Evolution of UK national research institute in
policy context
A substantial achievement of the Farr Institute and its funders
was the founding of its larger successor HDR UK. The key
differences and similarities of the two organisations are shown
in Table 1. This expansion from Farr Institute to HDR UK
was recommended by the Farr Institute International Advisory
Board in 2015, and much of the evolution of the Farr (see time-
line in Supplementary Fig 3) was in preparation for this change.
Lessons learned from the Farr Institute informed the develop-
ment of HDR UK’s science strategy [33] (with 6 themes in
human phenome project, AI, multiomics and multi-disease ae-
tiology, clinical trials, digital health insights, and public health)
and delivery, establishing a new single legal entity, single Di-
rector and Board, working via consortium agreements. The
expanded research organisation partnerships in HDR UK now
includes the majority of UK research organisations with signif-
icant expertise in data science for health. During 2013-18 the
UK underwent a set of profound political, societal and policy
changes relevant to data science for health: implemented the
most significant reforms of the NHS of a generation in 2013
(establishing NHS Digital, Public Health England), enduring
multiple crises of public trust over the use of data (care.data,
Royal Free NHS Foundation Trust and Google DeepMind),
the most significant changes in data protection legislation in
a generation (as a result of the EU General Data Protection
Regulation), two General Elections, and the historic referen-
dum to leave the EU (see timeline in Supplementary Fig 4).
International context of national research ini-
tiatives in data science for health
The Farr Institute and HDR UK have sought to learn from
the differing approaches among countries and jurisdictions to
advancing data science for health. For example, in order to
facilitate learning across national boundaries, the Farr Insti-
tute jointly funded exchange fellowships with the Institute of
Clinical Evaluative Sciences in Ontario, Canada. Currently, as
far as the authors are aware, other countries have not estab-
lished a national research institute dedicated to data science
for health directly analogous to the Farr Institute or HDR UK.
There is a need for strategic collaboration across national bor-
ders in data science for health [34], with proposals for working
across national borders in Nordic countries [4].
The UK, informed by the ability of smaller countries such
as Denmark [35] to deliver nationwide research built on an
array of linkable record resources, as established the national
institute in order to meet the challenging goal of nationwide
research in a country of 65 million people. Some of the
challenges facing the Farr Institute, and now HDR UK, are
common to any research initiative based on catalysing inter-
institutional and inter-disciplinary collaboration. Previous pol-
icy reports have recommended the need for intra-national
methodological developments in data science for health as an
important basis for international collaboration [36].
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Defining central scientific challenges: biomed-
ical
The central scientific challenge set out by the 2011 funding
competition (supplementary MRC 2011 Funding call ) con-
cerned record linkages. After the Farr Institute was estab-
lished, the international advisory board, funders and directors
recognised the need to more clearly identify the key research
challenges which could only or best be addressed with cen-
tres coming together as a single national research institute.
This led, in 2015, to the development of the science themes
of discovery science, precision medicine, trials, learning health
systems and public health outlined in Figure 2.
Defining central scientific challenges: scale
Providing a ‘more powerful telescope’ by enabling EHR and
administrative data at greater scale (larger sample sizes) is
part of the central scientific challenge. Although nationwide
primary care data exist in the UK with the 65 million popu-
lation held by four GP system suppliers, they are not brought
together in a single dataset for research purposes. The Farr
Institute was publishing on 6% samples at 2018. The largest
collections are held by Q-Research, Clinical Practice Research
Datalink (CPRD) and System One, and there are more exten-
sive collections of linked GP and other care data in the regions
and devolved administrations, such as the Secure Anonymised
Information Linkage (SAIL) system in Wales and the Con-
nected Health Cities’ Trustworthy Research Environments in
North England’s four regions. The levers for increasing scale
do not sit in research institutes, but with data controllers and
the legal and political environments. The Farr Institute paved
the way for federation of research data queries and distributed
analytics across regional data aggregations.
Defining central scientific challenges: across
the translational cycle
Most biomedical research disciplines are focused on a particu-
lar phase of the translational cycle: the Farr Institute demon-
strated that a distinctive contribution of data science for health
is that EHR and other sources of data ‘in the wild’ can link
investigators across all phases of the translational research cy-
cle. The Farr Institute made a start in the UK: the ambition,
which HDR UK has taken on, is to constructively disrupt cur-
rent models of evidence-based medicine, clinical practice and
translational research, including the way that research is or-
ganised and funded.
Defining central scientific challenges: record
linkages
The original 2011 funding competition (supplementary MRC
funding call document) sought centres to “undertake and pro-
mote innovative linkage and analysis of large health related
data sets”. The top 100 Farr Institute publications reported
102 unique data sets, but record linkages were not reported
consistently, nor in sufficient detail to know which sources had
been linked, and whether any linkage was new. In Wales
(SAIL), Scotland (eIDRIS) and some English regions (Con-
nected Health Cities) there are data linkage and trustworthy
research environments that have fuelled numerous research
outputs. For example, in Wales primary care data (including
text) are linked to hospital admissions data, dispensed pre-
scribing, blood laboratory values and a wide range of socio-
economic data. This breadth and depth of linkages, and their
sustained accessibility by researchers, have not emerged across
larger populations such as England. In England the opportu-
nities for developing a growing, sustainable environment for
record linkages were severely curtailed by care.data and have
only recovered in the regional devolved approaches such as
the NHS England Local Health and Care Record Exemplars.
In annotating Farr Institute research publications, we found
variable clarity on reporting of record linkage and were not
able to easily identify how many linkages had been reported
which were new and which might be readily accessible to fu-
ture researchers.
Defining central scientific challenges: data
quality
Improvements in the quality of health record data, an interna-
tionally recognised challenge [35], was not an aim of the orig-
inal funding competition, nor did it become a co-ordinated
national focus in the Farr Institute, in part because the key
influences lie in the NHS. Nonetheless the Farr Institute did
deliver an open portal, CALIBER, for EHR phenotyping algo-
rithms, along with evaluations of data quality and validations.
Demonstrating how the central challenges
might be solved
The Farr Institute transformed the UK’s ability to bring non-
consented individual-level health data into trustworthy envi-
ronments and make them available for other researchers, based
on specifically approved projects. Nonetheless, there remain
many different data governance environments and processes
for data access for research, with much room for harmoni-
sation and streamlining. We demonstrate here how the Farr
Institute published on over 100 EHR and administrative data
sources; in some situations these were the first research use
of these data. Despite the undoubted progress reported here,
the EHR data sources reported represent a tiny proportion of
available data.
How the challenge may be addressed: pheno-
typing
The Farr Institute demonstrated approaches to the major chal-
lenge of defining disease and health related traits with diverse
EHR and other data. The development of the open CALIBER
portal for EHR phenotype algorithms and their validations pro-
vides a basis on which to develop a national online facility to
integrate data, methods and investigators for EHR phenotyp-
ing. Recent work from the Farr Institute demonstrated multi-
ple code set validations of the 308 most common diseases and
conditions, providing a ‘chronological map’ of human health
from birth to death [37,38]. A key challenge for the future is
to develop approaches which provide a degree of consistency
and replicability across jurisdictions and national borders.
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Creating novel interactions among groups of
scientists
We visualised an ‘explosion’ of co-author networks. This re-
flects the willingness of investigators to self-identify with the
Farr Institute, as there was no monitoring of this practice at
central or national level, as well as extensive collaborations be-
tween those with and without Farr Institute funding. The top
ten most cited Farr publications have been cited in total >3200
times. The capital investment allowed the co-ordinated estab-
lishment, for the first time in the UK, of physical homes (build-
ings) for the emerging field: 6421m2 of dedicated, branded
space allowing research disciplines, technical specialists, NHS
IT professionals and industry partners to ‘breathe the same
air’. Beyond 2018, the capital investment in the Farr Institute
has had an enduring effect, with most of the physical estate
now being dedicated to HDR UK activities. The Farr Insti-
tute co-sponsored substantial expansion of scientific confer-
ences: >850 delegates from 13 countries at Manchester 2017
meeting (>3 times larger than 2013 conference). Two new
journals were established (International Journal of Population
Data Science and Journal of Learning Health Systems) with
Farr investigators Kerina Jones and Iain Buchan as editors.
There remain major challenges in bringing scientists and
technical specialists to work together across different institu-
tions and disciplines. Indeed the influential Research Excel-
lence Framework, provides financial incentives to universities
to compete, rather than collaborate [39].
Impact on Innovation and Industry Partner-
ships
Universities within the Farr Institute Centres collaborated with
industrial partners on research (e.g. Astra Zeneca, see Table
5), and training (e.g. masters courses with an option for stu-
dents to complete their dissertation as interns in industry).
However with 21 university partners the Farr Institute was not
able to sign strategic industry partnerships.
Training new types of experts
At masters, short-course and leadership levels, the Farr Insti-
tute had a substantial effect on teaching and training. The
Farr Institute evolved its training opportunities in response to
the growing need for data science as a discipline and in lead-
ership, neither of which were explicitly envisaged in the 2011
original funding call (supplementary MRC 2011 Funding call).
Demonstrating impacts in society: on health
and healthcare
The Farr Institute carried out research underpinning policies
and recommendations to change clinical and public health
practice, and shaping government policy in health data man-
agement and digital health innovation. We provide here exam-
ples of specific research findings and their relation to changes
in policy and recommendations. However, the Farr Institute
had no central mechanism of identifying such influence (Ta-
ble 5 is likely incomplete), nor of prospectively following re-
search through policy recommendations to measure changes in
health. In some cases Farr research may have impacts in later
years; HDR UK might usefully establish a more systematic
approach.
Demonstrating impacts in society: public en-
gagement and trust
The Farr Institute directly funded the involvement and en-
gagement of the public and patients in research using patient
data. In 2013 there were no national campaigns involving pa-
tients and the public in research on patient data. By 2018, the
Farr Institute had delivered influential national campaigns in
public engagement with the ‘100 ways’ case studies, explain-
ing to patients and public examples of the benefits of Farr
Institute research (13,000 followers and subscribers), and the
#datasaveslives campaign, which has generated more than
50,000 retweets. In addition, the Farr Institute contributed
to the Understanding Patient Data Wellcome Trust initiative
[40]. The Farr Institute established public panels, a network of
over 50 regular public contributors, and using a range of de-
liberative methods engaged members of the public in dialogue
around the ways that data are used in health research; consult-
ing them on research and governance practices and involving
them in agenda-setting and decision-making processes.
Limitations and Challenges
We identify five important limitations to this evaluation and
briefly discuss how these limitations might be addressed for
others evaluating inter-institutional, inter-disciplinary research
initiatives. First, the challenge of attribution: would the
changes in each domain which we catalogue here have hap-
pened anyway, in the absence of the Farr Institute? Because
the funding of the Farr was intended to catalyse and leverage
a range of activities, rather than to wholly fund specific ac-
tivities, it is seldom possible to prove attribution robustly.This
challenge of attribution is illustrated with research publica-
tions. In nearly all research publications analysed in this eval-
uation, the Farr Institute was one of several funders, and co-
authors with Farr funding are usually among a larger group
of co-authors without Farr funding. The Farr Institute did
not have an intra-mural programme of research fully funded
by the Farr awards, which were initially made to build four
centres. Unsurprisingly therefore, the major peer-reviewed sci-
entific outputs of the Farr were not published by all four cen-
tres together. This illustrates the challenge of transparent and
publicly accessible attribution to a national institute.
Second, the Farr Institute did not design a prospective
evaluation at the outset and thus the evidence presented here
has inherent limitations of a post hoc evaluation. A key les-
son learned was the importance of establishing at the outset
national data systems allowing research about research ideally
in near real time. These key data elements include items that
currently do have unique identifiers: Farr investigators (iden-
tified by ORCID iDs), their publications (identified by PMID),
but also the Farr Institute could have done more to advance
central cataloguing (with unique identifiers) of datasets, record
linkages, projects, disciplines, employing organisation and de-
partment, partner organisations (e.g. NHS). Indeed, much of
the evidence reported in this evaluation could not have been
identified by others, and some of it remains not open to inde-
pendent scrutiny.
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Third, evaluations require comparisons and ours was lim-
ited to the first and final 30 months (a ‘before and after’
design). We believe it would be informative in future to com-
pare with other inter-institutional, inter-disciplinary national
research institutes (including for example in the UK, the Crick,
Turing, Sanger, Dementia Research Institute).
Fourth, our evaluation was neither external to nor inde-
pendent of, the Farr Institute. However, the Farr Institute did
receive regular external feedback, from both the International
Advisory Board and the funder consortium. Since the Farr
Institute ended in 2018, there were no potential conflicts of
trying to seek further funding.
Fifth, we recognize that there is a role for qualitative ev-
idence, for example through interviews with stakeholders as
well as critics, which might add insights and highlight further
critical challenges on many of the domains which we sought
to evaluate, including the nature, and extent, of any changes
attributable to the Farr Institute.
Conclusion
In the UK, the Farr Institute played a significant role in begin-
ning to grow the field of data science for health. In 2013 there
was little UK-wide co-ordination or visibility of research ca-
pabilities, including methods development or training in data
science for health, and by 2018 this had been transformed.
The importance of a national research institute in this field is
evidenced by the UK’s expanded commitment to HDR UK.
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